| CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) | Effects of Hypoxias and Scaffold Architecture on Rabbit Mesenchymal Stem Cell Differentiation towards a Nucleus Pulposus-Like Phenotype The data showed the promise of using 3D nanofibrous scaffolds in combination with TGF-β1 and hypoxic induction to regenerate functional nucleus pulposus grafts for intervertebral disc replacement. [Biomaterials] Mechanical and Biological Properties of Keratose Biomaterials The degraded keratose was observed to remodel with the natural collagen extracellular matrix, verifying the benefit of using keratose as a temporary matrix for regenerative medicine applications. [Biomaterials] Elucidating the Mechanobiology of Malignant Brain Tumors Using a Brain Matrix-Mimetic Hyaluronic Acid Hydrogel Platform Researchers synthesized brain-mimetic extracellular matrices based on hyaluronic acid with a range of stiffnesses that encompasses normal and tumorigenic brain tissue and functionalized these materials with short Arg-Gly-Asp (RGD) peptides to facilitate cell adhesion. [Biomaterials] Influence of Chondroitin Sulfate and Hyaluronic Acid on Structure, Mechanical Properties, and Glioma Invasion of Collagen I Gels To mimic the extracellular matrix surrounding high grade gliomas, composite matrices composed of either acid-solubilized or pepsin-treated collagen and the glycosaminoglycans chondroitin sulfate and hyaluronic acid are prepared and characterized. [Biomaterials] Bioprinting of Growth Factors Onto Aligned Sub-Micron Fibrous Scaffolds for Simultaneous Control of Cell Differentiation and Alignment Herein, oriented sub-micron fibers, which are morphologically similar to musculoskeletal extracellular matrix, were spatially patterned with growth factors using an inkjet-based bioprinter to create geometric and biochemical cues that direct musculoskeletal cell alignment and differentiation in vitro in registration with fiber orientation and printed patterns, respectively. [Biomaterials] Regeneration of Uterine Horns in Rats by Collagen Scaffolds Loaded with Collagen-Binding Human Basic Fibroblast Growth Factor In the present study, a collagen targeting basic fibroblast growth factor (bFGF) delivery system was constructed by a collagen membrane loaded with bFGF fused a collagen-binding domain to the N-terminal which limits the diffusion of bFGF from collagen. [Biomaterials] Artificial Extracellular Matrix Proteins Containing Phenylalanine Analogues Biosynthesized in Bacteria Using T7 Expression System and the PEGlyation In vivo incorporation of the phenylalanine analogues into an artificial extracellular matrix protein (aECM-CS5-ELF) was accomplished by using a bacterial expression host that harbors a mutant phenylalanyl-tRNA synthetase with an enlarged binding pocket. [Biomacromolecules] Peculiarities of the Extracellular Matrix in the Interstitium of the Renal Stem/Progenitor Cell Niche The applied technique appears to be a suitable method to illuminate the interstitium in stem/progenitor cell niches of specialized tissues, the microenvironment of tumors and extension of degeneration. [Histochem Cell Biol] Overexpression of HTRA1 Leads to Ultrastructural Changes in the Elastic Layer of Bruch’s Membrane via Cleavage of Extracellular Matrix Components The data implicate that HTRA1 overexpression leads to an altered elastogenesis in Bruch’s membrane through fibulin 5 cleavage. It highlights the importance of extracellular matrix related proteins in the development of age-related macular degeneration (AMD) and links HTRA1 to other AMD risk genes such as fibulin 5, fibulin 6, ARMS2 and TIMP3. [PLoS ONE] Human Mesenchymal Stem Cells Seeded on Extracellular Matrix Scaffold: Viability and Osteogenic Potential A new combination between cells and ECM-scaffold, containing extracellular matrix (ECM) has here been analyzed. [J Cell Physiol] |
| INDUSTRY NEWS | Halozyme Therapeutics Reports Second Quarter 2011 Financial Results Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, reported financial results for the second quarter of 2011 and discussed recent business progress. [Halozyme Therapeutics, Inc. Press Release] |
|
|
|